Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anil Singhal

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Cancer|October 10, 2003
A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumorsRobert A Lustig, Thomas J Vogl, David Fromm, et al.
British Journal of Haematology|July 20, 2016
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myelomaMaría-Victoria Mateos, Miguel Granell, Albert Oriol, et al.
Molecular Cancer Therapeutics|October 22, 2017
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid TumorsElaine T Lam, S Gail Eckhardt, Wells Messersmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple MyelomaRavi Vij, Rajneesh Nath, Daniel E H Afar, et al.
British Journal of Haematology|July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growthMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
The New England Journal of Medicine|June 3, 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaSagar Lonial, Meletios Dimopoulos, Antonio Palumbo, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cancer|October 10, 2003
A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumorsRobert A Lustig, Thomas J Vogl, David Fromm, et al.
British Journal of Haematology|July 20, 2016
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myelomaMaría-Victoria Mateos, Miguel Granell, Albert Oriol, et al.
Molecular Cancer Therapeutics|October 22, 2017
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid TumorsElaine T Lam, S Gail Eckhardt, Wells Messersmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple MyelomaRavi Vij, Rajneesh Nath, Daniel E H Afar, et al.
British Journal of Haematology|July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growthMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
The New England Journal of Medicine|June 3, 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaSagar Lonial, Meletios Dimopoulos, Antonio Palumbo, et al.
Pageof 2